Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.
Inconsistent dosing practices for a leukemia maintenance drug after transplant explain why some patients benefit while others don't, pointing toward standardization.
Regional practice variations in post-HCT gilteritinib administration (dose, timing, duration) significantly impact clinical benefit in FLT3-ITD AML, highlighting critical gaps in protocol standardization for maintenance therapy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- multicenter retrospective cohort/registry analysis (international)
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Blood Adv
Why it surfaced
Post-HCT gilteritinib is standard-of-care in FLT3-ITD AML, but real-world implementation is inconsistent. This analysis from major transplant centers provides practice-level evidence to optimize the benefit of this maintenance strategy. Directly actionable for oncology/BMT program review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.